AL-LAD vs DMT
A side-by-side research comparison of AL-LAD and DMT across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AL-LAD | DMT |
|---|---|---|
| Full name | 6-Allyl-6-nor-LSD | N,N-Dimethyltryptamine |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (research compound) |
| Mechanism | Activates serotonin 5-HT2A receptors, like LSD. | Activates serotonin 5-HT2A receptors, producing vivid changes in perception. When taken orally in ayahuasca, an MAO inhibitor is needed so it is not broken down too quickly. |
| Molecular weight | 349.47 g/mol | 188.27 g/mol |
| Half-life | ~3-4 hours | ~10-15 minutes |
| Bioavailability | Oral | Inhaled/injected (very short); oral only with an MAO inhibitor |
| Typical dose | Varies by individual and setting | Controlled dosing in clinical studies |
| Frequency | Occasional | One to a few supervised sessions |
| Route | Oral | Inhalation or IV in research; oral as ayahuasca |
AL-LAD reported benefits
- Shorter than LSD
- Reportedly less anxious
- Strong visual component
- Lysergamide research compound
DMT reported benefits
- Studied for depression
- Very short experience aids research design
- Used to study consciousness
- Long traditional use as ayahuasca
Related comparisons
Research and educational reference only. Not medical advice.